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Introduction: MicroRNAs (miRNAs) have been implicated in governing lineage specification and differentiation in
multiple organs; however, little is known about their specific roles in mammopoiesis. We have determined the
global miRNA expression profiles of functionally distinct epithelial subpopulations in mouse and human mammary
tissue, and compared these to their cognate transcriptomes and epigenomes. Finally, the human miRNA signatures
were used to interrogate the different subtypes of breast cancer, with a view to determining miRNA networks
deregulated during oncogenesis.
Methods: RNA from sorted mouse and human mammary cell subpopulations was subjected to miRNA expression
analysis using the TaqMan MicroRNA Array. Differentially expressed (DE) miRNAs were correlated with gene expression
and histone methylation profiles. Analysis of miRNA signatures of the intrinsic subtypes of breast cancer in The Cancer
Genome Atlas (TCGA) database versus those of normal human epithelial subpopulations was performed.
Results: Unique miRNA signatures characterized each subset (mammary stem cell (MaSC)/basal, luminal progenitor,
mature luminal, stromal), with a high degree of conservation across species. Comparison of miRNA and transcriptome
profiles for the epithelial subtypes revealed an inverse relationship and pinpointed key developmental genes.
Interestingly, expression of the primate-specific miRNA cluster (19q13.4) was found to be restricted to the MaSC/basal
subset. Comparative analysis of miRNA signatures with H3 lysine modification maps of the different epithelial subsets
revealed a tight correlation between active or repressive marks for the top DE miRNAs, including derepression of
miRNAs in Ezh2-deficient cellular subsets. Interrogation of TCGA-identified miRNA profiles with the miRNA signatures of
different human subsets revealed specific relationships.
Conclusions: The derivation of global miRNA expression profiles for the different mammary subpopulations provides a
comprehensive resource for understanding the interplay between miRNA networks and target gene expression. These
data have highlighted lineage-specific miRNAs and potential miRNA–mRNA networks, some of which are disrupted in
neoplasia. Furthermore, our findings suggest that key developmental miRNAs are regulated by global changes in
histone modification, thus linking the mammary epigenome with genome-wide changes in the expression of genes
and miRNAs. Comparative miRNA signature analyses between normal breast epithelial cells and breast tumors
confirmed an important linkage between luminal progenitor cells and basal-like tumors.* Correspondence: visvader@wehi.edu.au
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The ductal epithelial networks that characterize mouse
and human mammary tissue appear to comprise an
analogous cellular hierarchy: multi-potent mammary
stem cells (MaSCs) reside at the apex of the hierarchy
and are capable of differentiation along the myoepithe-
lial/basal lineage or the luminal lineage to yield mature
ductal and alveolar cells [1–6]. The precise nature of the
intermediate cell types remains unclear but two or three
distinct luminal progenitor subsets have been prospect-
ively isolated from mouse and human mammary tissue,
respectively [4, 7–9]. Several functional studies have used
a candidate approach to identify regulators of self-renewal,
lineage commitment and differentiation programs (re-
viewed in [10]). Furthermore, genome-wide transcriptome
analyses [11, 12] of mouse mammary epithelial subsets
have identified a number of potential regulators of mam-
mary gland development. The definition of numerous
conserved pathways across species has highlighted those
that are likely to be involved in cell-fate decisions and
lineage differentiation [12]. Moreover, the epigenome has
been implicated in playing a critical role in regulating such
decisions within the epithelial compartment of the normal
mammary gland [13, 14].
There is increasing evidence that microRNAs (miRNAs)
regulate a wide range of biological processes, including
maintenance of cell identity, differentiation and apoptosis
[15–17]. miRNAs, small non-coding RNA molecules that
inhibit translation or trigger mRNA decay [15, 17], have
been implicated in both mammary gland development
and breast tumorigenesis. In a large-scale study, the ex-
pression of 318 miRNAs was assessed during different
stages of development, leading to the observation that
miRNAs can be expressed in coordinated clusters, and
that global miRNA and mRNA expression are significantly
lower in lactation and early involution [18]. In the mouse
mammary epithelial cell line, Comma-Dβ [19], the expres-
sion of miR-205 and miR-22 but not let-7 and miR-93
was linked to progenitor-like properties, while miR-200c
appears to function within the basal cell compartment of
normal breast tissue [20]. Interestingly, miR-200c targets
the mRNA encoding BMI1, a key regulator of the self-
renewal of stem cells in multiple tissues. MiR-193b also
has been implicated in regulating mammary stem cell
activity in vivo and may serve an additional function in
controlling the alveolar differentiation during pregnancy
[21]. In the context of breast cancer, many miRNAs have
been reported to undergo deregulation, inferring an im-
portant role in controlling proliferation versus differenti-
ation decisions. For example, miR-205 is one the most
significantly downregulated miRNAs in human breast
cancer relative to normal tissue [22]. Moreover, miRNA
signatures that distinguish breast tumors of different sub-
types from normal tissue have been described [23]. Tounderstand the consequences of deregulated miRNA net-
works, it is essential to characterize the normal expression
patterns and roles of miRNAs in the epithelial differenti-
ation hierarchy. Here we sought to determine the global
miRNA expression profiles of discrete cellular subpopula-
tions within normal mouse and human mammary tissue.
Comparative analyses of miRNA signatures with gene ex-
pression and histone modification profiles of the epithelial
subsets revealed candidate miRNAs that are likely to exe-
cute important roles in mammary epithelial specification
and differentiation.
Methods
RNA preparation and quantitative PCR analysis
The cellular subsets isolated by flow cytometry have
been previously described [12]. Mice were on a pure
FVB/N background. All experiments were approved by
the Animal Ethics Committee of the Walter and Eliza
Hall Institute of Medical Research, and the care of ani-
mals was in accordance with institutional guidelines.
Experiments using human tissue obtained from the
Victorian Cancer Biobank, each with patient consent, were
approved by the Human Research Ethics Committees of
The Walter and Eliza Hall Institute of Medical Research
and Melbourne Health.
Total RNA or miRNA populations were isolated
from primary mammary cell subpopulations using the
miRNeasy kit (Qiagen, Germany). Notably, identical cell
pellets (following sorting) were used for mRNA and
miRNA preparation: the transcriptomes for these subsets
are reported in Lim et al. [12]. Reverse transcription was
carried out using oligo(dT) primer and SuperscriptIII re-
verse transcriptase (Invitrogen, MA, USA). For miRNA
samples, reverse transcription was performed using a
target-specific stem loop primer and reverse transcriptase
(Invitrogen) according to the manufacturer’s protocol.
Quantitative RT-PCR was carried out using a Rotorgene
RG-6000 (Corbett Research, Australia) under the following
conditions: 2 minutes at 50 °C and 10 minutes at 95 °C
followed by 35 cycles consisting of 15 s at 95 °C and 60 s at
60 °C. Gene expression was determined using Rotor-Gene
software (version 1.7).
microRNA expression profiling
At least three biological replicates of RNA from each
human and mouse cell subpopulation were profiled for
miRNA expression using a Taqman array system (Applied
Biosystems, MA, USA). Complementary DNA (cDNA)
was prepared using TaqMan miRNA Reverse Transcrip-
tion Kit (ABI 4366596) and the Megaplex RT primer pools
(mouse v2.0 ABI #4401012 and human v2.0 ABI #4401091)
according to the manufacturer’s protocol. For each sam-
ple, cDNA was made using appropriate Megaplex pri-
mer pools and 3 μl RNA as a template. Each pool was
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ter Mix (ABI #4391128) and Megaplex preAmp primers
(mouse v2.0 ABI #4401012 and human v2.0 ABI #4401091).
Quantitative RT-PCR was performed on an ABI 7900HT
machine using either the TaqMan Rodent MicroRNA
Array Set v2.0 (ABI #4400239) or Taqman Human Micro-
RNA Set v2.0 (ABI #4400238), Taqman Low Density Array
plates and Universal PCR Master Mix (ABI #4364341) ac-
cording to the manufacturer’s protocol. U6 was included as
an endogenous control and Arabidopsis thaliana-miR159a
was included as a negative control on each plate. Ct (cycle
threshold) values were exported using SDS v2.3 and RQ
Manager v1.2 software (Applied Biosystems, MA, USA),
with automatic baseline and a manual Ct threshold of 0.2.
Statistical analyses of microRNA expression values in
normal cell subpopulations
The maximum measurable Ct value was 40, so Ct values
were transformed to a log2 expression scale by subtracting
the Ct values from 40.5. Statistical analysis was carried out
using the limma software package [24]. The expression
values were normalized using cyclic loess normalization
[25] with house-keeping probes up-weighted 100-fold.
The cyclic method was set to “affy”, the loess span was
0.7, and five cyclic iterations were used. For mouse, the
snRNA U6 was the house-keeping probe. For human, U6,
RNU6B, RNU24, RNU43, RNU44 and RNU48 were all
treated as house-keeping probes. For both mouse and hu-
man, probes were filtered out as unexpressed if they failed
to achieve a normalized value of 2 in at least three sam-
ples. The RT-PCR expression data is available from the
Gene Expression Omnibus as superseries GSE67056.
Comparisons were made between cell populations using
empirical Bayes t- and F-statistics [26]. The false discovery
rate (FDR) was controlled below 0.05 using the method of
Benjamini and Hochberg [27]. For each subpopulation
(MaSC/basal, luminal progenitor, and mature luminal),
signature probes were defined as those that were differen-
tially expressed (DE) versus the average of the other two
cell subpopulations. Separate analyses were conducted for
mouse and human. A combined analysis was also con-
ducted using the mouse and human data together, using a
linear model that included a covariate to adjust for differ-
ences between species. For the combined analysis, mouse
and human Taqman probes were matched by miRNA
symbols.
Correlation of microRNAs and putative target mRNAs
TargetScan [28] was used to identify putative target
mRNAs for each miRNA. ROAST gene set tests [29]
were applied to test whether the expression level of each
miRNA was negatively correlated with the expression of
its target mRNAs. The ROAST tests were conducted
using mRNA expression values obtained from IlluminaBeadChips as previously published [12]: GEO series
GSE19446 for mouse data and GSE16997 for human
data. A one-sided P-value was obtained for each miRNA
to test whether the average log-fold expression change
of the target genes was in the opposite direction to that
of the miRNA.
Gene ontology (GO) analysis was conducted using the
goana function of the limma package. Genes were se-
lected as DE for the purposes of GO analysis if they were
(i) a target of a DE miRNA and (ii) DE in the mRNA
microarray data with FDR <0.2 in the inverse direction
to the miRNA.
Analysis of microRNA signatures in breast cancer subtypes
miRNA profiles of breast cancer tumors were down-
loaded from The Cancer Genome Atlas (TCGA) Data
Portal [30], specifically from the data directory bcgsc.ca_
BRCA.IlluminaHiSeq_miRNASeq.Level_3.1.17.0. Only
profiles of primary solid tumors were used for this ana-
lysis. PAM50 tumor subtype calls were obtained for each
sample from the TCGA analysis working party (CM Perou
and KA Hoadley, personal communication). The data
consist of Illumina HiSeq read counts for each miRNA in
each sample. Samples with the same analyte IDs were
treated as technical replicates and were combined by sum-
ming their read counts for each miRNA. Similarly, counts
for different isoforms of the same miRNA were summed.
miRNAs were filtered as unexpressed if they failed to
achieve at least one read per million in at least 29 samples.
This left data on 451 miRNAs for 720 tumor samples.
Using the edgeR package, counts were normalized by
the trimmed mean of M-values method [31] and then
converted to log2 counts per million with a prior count
of 0.25.
For each tumor sample, miRNA expression signature
scores were computed to measure similarity with MaSC-
enriched, luminal progenitor and mature luminal cells,
using a method similar to that used previously for mRNA
expression scores [2]. Given a set of signature genes for
each cell subset and associated log2 fold changes, expres-
sion scores were computed as sum(logFC * logCPM)/sum-
s(abs(logFC)), where logFC is the log2 fold change for a
miRNA between normal cell subsets in the PCR data and
logCPM is the log2 count per million for the miRNA from
the RNA-seq data. The sum is taken over all miRNAs. An
expression score was computed for each tumor and epi-
thelial cell subset.
Analysis of epigenetic modifications of microRNA loci
Genome-wide ChIP-seq profiles of H3K4me3 and
H3K27me3 histone marks were obtained previously for
the mouse MaSC/basal, luminal progenitor and mature
luminal cell subsets [14]. Sequence data is available from
the Gene Expression Omnibus series GSE43212. For this
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mm10 using the subread aligner [32]. Genomic locations
of miRNAs were downloaded from miRBase [33]. Read
counts were obtained for a genomic interval extending 3
kb upstream and 3 kb downstream from the body of
each miRNA using featureCounts [34]. The same gen-
omic interval was used for both 3′ and 5′ isoforms of
the same miRNA where these existed. A differential
binding analysis between the three epithelial subsets was
undertaken using the edgeR Bioconductor package [35].
Log2 fold changes in binding intensity between the three
epithelial subsets were computed for each miRNA using
edgeR’s glmFit function, setting the negative binomial
dispersion to 0.05 and the prior count to 1 [36]. The
prior count has the effect of shrinking the log2 fold
changes slightly towards zero to avoid unstable fold
changes for low counts. The ChIP-seq log2 fold changes
were correlated with miRNA expression log2 fold changes
using regression through the origin.
Results
Lineage-specific expression of mammary microRNAs
Freshly sorted cellular subsets corresponding to MaSC/
basal, luminal progenitor, mature luminal and stroma
cells were prospectively isolated from mouse and human
mammary glands. In the mouse, the immunophenotypes
of the subpopulations [3] are: CD29hiCD24+ (MaSC/basal),
CD29loCD24+CD61+ (luminal progenitor), CD29loCD24+
CD61– (mature luminal) and CD29–CD24– (stroma). For
human breast, the phenotypes [2] are: CD49fhiEpCAM–/lo
(MaSC/basal), CD49f+EpCAM+ (luminal progenitor),
CD49floEpCAM+ (mature luminal) and CD49f–EpCAM–
(stroma). Of note, the MaSC/basal population comprises
stem cells, putative basal progenitor cells and mature
myoepithelial cells. The miRNA studies were performed
on the same sorted human and mouse cellular subsets as
used previously for mRNA expression profiling using mi-
croarrays [12]. As for the transcriptome study, a minimum
of three biological replicate samples were profiled from
each cell subpopulation: cDNA was prepared for miRNA
profiling from the small RNA fraction (less than 200 bp),
and mouse and human Megaplex RT Primer Pools con-
taining primers for either 585 mouse or 667 human
miRNAs (plus species-specific controls) were utilized. A
pre-amplification step (12 cycles) was incorporated to im-
prove the chance of detecting miRNAs expressed at very
low levels. High throughput RT-PCR was used to generate
log2 expression values for all miRNAs and samples.
Each cellular subpopulation was marked by a distinct
miRNA expression pattern (Fig. 1). In both mouse and
human, stromal cells were well separated from the three
epithelial subpopulations (Fig. 1a). Differential expres-
sion analysis comparing the stroma subset with the aver-
age of the three epithelial subsets revealed 276 miRNAsthat distinguished stroma from the total epithelium in
mouse (Additional file 1: Table S1; FDR <0.05) and 181
in human (Additional file 2: Table S2; FDR <0.05).
The three epithelial subpopulations were also distinct.
Analysis of variance found 221 miRNAs that were DE
between the MaSC/basal, luminal progenitor and mature
luminal populations in mouse (Additional file 3: Table S3,
FDR <0.05) and 209 in human (Additional file 4: Table S4,
FDR <0.05). The greatest expression differences were as-
sociated with the MaSC/basal subsets. The progenitor and
mature luminal subpopulations showed relatively closer
expression profiles while still being distinct from each
other. Comparison of the MaSC/basal subset with the
average of the two luminal populations revealed 188 dif-
ferentially expressed miRNAs in mouse. Of these, 107
miRNAs were more highly expressed in the mouse
MaSC/basal subset and 81 were more highly expressed
upon restriction to the luminal lineage (Additional file 5:
Table S5; FDR <0.05). The same comparison in human
found 213 differentially expressed miRNAs between the
MaSC/basal subset and the luminal lineage, with 163 up-
regulated in the MaSC/basal subset and 50 in luminal cells
(Additional file 6: Table S6; FDR <0.05).
Conservation across species
To explore the mouse and human data together, a batch
correction was used to adjust for differences between
the two species and hierarchical clustering was applied
to all the mouse and human cell populations together
(Fig. 1b). This analysis was restricted to miRNA families
found in both species. The clustering confirmed a clear
separation between the stromal, MaSC/basal and lu-
minal cell populations, with all cell subsets clustering to-
gether despite species differences (Fig. 1b). In particular,
the mouse and human stromal populations clustered to-
gether despite known differences between stroma in the
two species. Mouse mammary stroma is known to com-
prise a higher proportion of adipocytes, whereas human
breast stroma is highly enriched for fibroblasts. The
homologous expression profiles between human and
mouse stroma suggest that either population might be
utilized to support human breast epithelial cells in cell-
based assays ex vivo.
A differential expression analysis of the combined mouse
and human expression profiles was conducted to find
miRNAs that showed the same pattern of differential ex-
pression between the epithelial subsets in both species.
Analysis of variance revealed 111 miRNAs that were con-
sistently differentially expressed between the three epithe-
lial subsets (FDR <0.05). A more focused comparison of
the MaSC/basal subset with the combined luminal subsets
found 108 differentially expressed miRNAs, of which 50
had higher expression in the MaSC/basal subset and
















Fig. 1 (See legend on next page.)
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Fig. 1 Global miRNA expression in sorted populations from mouse and human mammary glands. Mouse and human epithelial subsets are
marked by unique miRNA expression signatures. a Multi-dimensional scaling plots indicate clear separation of the mammary stem cell (MaSC)/
basal-enriched, luminal progenitor (LP), mature luminal (ML) and stromal subsets in both mouse (left panel) and human (right panel). Distances on
the plot represent the log2 fold change for a typical miRNA between the samples. Stromal cells are well separated from the epithelial subsets,
with a typical expression change of around 5 logs or 32-fold. The MaSC/basal subset is well separated from the luminal subsets with a typical
expression change of around 4 logs or 16-fold. b Combined heat map shows hierarchical clustering of all conserved miRNAs in mouse and
human epithelial subsets including stromal subsets (red = high expression; blue = low expression)
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population include miR-204 (may target ERα), miR-221/
222 (targets ERα and c-Kit) [37, 38], and miR-205 (targets
Pten and Bcl-2) [39, 40]. Luminal-restricted miRNAs in-
cluded miR-10a (targets KLF4 and PIK3CA) [41, 42], miR-
200a/b (targets EMT (epithelial mesenchymal transition)
genes) [43], miR-148a (targets Bim) [44] and miR-375 (tar-
gets PDK1) [45].
Target gene prediction and inverse correlation between
microRNA and mRNA expression in distinct subpopulations
To explore the potential biological functions of DE
miRNAs between mammary epithelial lineages, we identi-
fied putative target mRNAs for each miRNA. This was
achieved using the Targetscan program, which predicts
miRNA-binding sites in mRNA 3′ untranslated regions.
Many of the miRNAs specific to the MaSC/basal subset
(Additional file 3: Table S3 and Additional file 4: Table S4)
were observed to target key luminal-lineage mRNAs
including Gata3, Notch1, Elf5, c-Kit and Esr1 [11, 12].
Conversely, many luminal-specific miRNAs have been im-
plicated in targeting transcription factors that are re-
stricted to basal cells in the mammary gland such as Snai2
and Trp63 [11, 12]. Predicted target mRNAs for a num-
ber of miRNAs are shown in Fig. 2c. Many of these are
likely to be relevant to lineage restriction in the mam-
mary gland such as miR-203, which is expressed in lu-
minal cells and targets the basal-restricted genes Snai2
and Trp63 [46–48].
To rigorously test whether the DE miRNAs are in fact
regulating their putative mRNA target genes within a
given mammary lineage, we carried out Rotation Gene
Set Tests (ROAST) to assess whether the expression of
each miRNA was inverse correlated with that of its tar-
get genes during luminal commitment. The expression
levels of mRNA genes in the mouse and human MaSC/
basal, luminal progenitor and mature luminal subpopu-
lations were measured by microarrays as previously re-
ported [12]. This analysis confirmed that many of the
DE miRNAs between the MaSC/basal and luminal sub-
sets do show significant inverse correlations with their
target mRNAs, supporting the hypothesis that they
constitute an active regulatory mechanism (Additional
file 8: Table S8). This was true for both mouse and hu-
man. As a representative example, the inverse correlationis displayed by barcode plots for the mouse and human
versions of miR-200b (Fig. 2b), which is a key miRNA that
targets the EMT genes Zeb1 and Zeb2 [43].
GO enrichment analysis was used to examine the bio-
logical processes and molecular functions that are regu-
lated as basal stem/progenitor cells commit to the luminal
lineage. In particular, GO analysis was conducted on the
putative mRNA targets of miRNAs that were differentially
expressed between the MaSC/basal and luminal subsets.
This revealed that luminal-specific miRNAs tend to down-
regulate signaling pathways including cell differentiation,
cell development, and regulation of developmental pro-
cess in both mouse and human mammary epithelium
(Additional file 9: Table S9A and Additional file 10:
Table S10A), whereas MaSC/basal-specific miRNAs tend
to downregulate processes characteristic of differentiated
cells including intracellular localization, transport, organ-
elle, biosynthesis, secretion and cell–cell interaction path-
ways (Additional file 9: Table S9B and Additional file 10:
Table S10B).
Restricted expression of a primate-specific microRNA
cluster in the MaSC/basal subset
Analysis of human miRNA profiles revealed differential
expression of primate-specific miRNAs between the basal
and luminal epithelial subsets. Interestingly, the region lo-
calized to chromosome 19q13.4 harbors a miRNA cluster
that spans ~150 kb and encodes 50 miRNAs (C19MC,
Fig. 3a). The expression of these miRNAs has been re-
ported to be high during embryonic development and in
human embryonic stem cells [49, 50]. Significant expression
of miRNAs within this cluster (miR-512-3p, miR-512-5p,
mir-515-5p, miR-516b, miR-517a, miR-517c, miR-518b,
miR-518f, miR-519a and miR-519d) was observed in the
MaSC/basal population (Fig. 3b), whereas no highly ex-
pressed luminal-specific primate miRNAs were identified.
Targetscan analysis indicated RANK (TNFRSF11A), a
member of the TNF superfamily of receptors, and MCL-1,
a BCL-2 pro-survival family member, as potential target
genes. These observations are compatible with the very
low expression of Rank and Mcl-1 mRNA in the MaSC/
basal subset [12, 51]. Moreover, the luminal lineage-
restricted genes, ERα and ELF5, were predicted to be
targeted by DE primate-specific miRNAs (Fig. 3c). The

































































































Fig. 2 (See legend on next page.)
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Fig. 2 Inverse correlation between differentially expressed miRNAs in specific subpopulations and their transcriptomes. Lineage-specific miRNAs
are conserved between mouse and human mammary tissue. a Schematic representation of Rotation Gene Set Test (ROAST) analysis [29]. Mouse
and human Taqman probes were matched by miRNA symbols obtained from the miRNA database (miRBase) and TargetScan was used to relate
miRNAs to target mRNAs. ROAST tests were performed to detect miRNAs that are most negatively correlated with their target mRNAs. b Barcode
plots showing the expression patterns of the mouse and human mRNA targets of the conserved luminal-specific miR-200b. Genes are ranked in
terms of relative expression from highest in MaSC/basal cells (MS) to highest in luminal cells. Target genes are marked with vertical bars and the
worm shows relative enrichment. The target genes tend to be less highly expressed in the luminal than the MaSC/basal subset. c Predicted target
genes for the top 20 conserved differentially expressed miRNAs in the two major populations. DE differentially expressed, miRNA miR microRNA,
Lum combined luminal progenitor and mature luminal cells
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ferential expression amongst the human breast epithelial
subsets.
Comparison of microRNA signatures for normal human
breast epithelial subpopulations versus breast cancer
subtypes
Breast cancer has been stratified into at least five mo-
lecular subtypes [54] and miRNA profiling of 101 pri-
mary breast tumors revealed differential expression of
miRNAs between these different subgroups [55]. More-
over, large-scale miRNA profiling of breast cancers carried
out under the TCGA project has provided a comprehen-
sive list of differentially expressed miRNAs between the
different subtypes [56]. Here we utilized miRNA signa-
tures to identify potential relationships between normal
human epithelial subsets and tumors of different molecu-
lar subtypes, analogous to that performed using mRNA
signatures [2]. The MaSC/basal miRNA signature was
found to be highest in the normal-like subtype of breast
cancer (P < 1.6 × 10–6), while the mature luminal signa-
ture was closest to the luminal B subtype (P < 9.4 × 10–5)
(Fig. 4a). Interestingly, the luminal progenitor miRNA sig-
nature was highest in the basal-like subtype relative to all
other subtypes (P < 1.4 × 10–9), reminiscent of that ob-
served for their transcriptomes [2]. Interrogation of the
TCGA database for expression of DE primate-specific
miRNAs (listed in Fig. 3c) revealed considerable enrich-
ment of miR-516a and miR-519a in basal-like tumors
(Fig. 4b; P < 1.9 × 10–5 and P < 5.3 × 10–9, respectively), in
contrast to the other miRNAs, which did not demonstrate
enrichment (data not shown).
Correlation of microRNA profiles with epigenetic
modification
We recently established the genome-wide histone methy-
lation profiles for the MaSC/basal, luminal progenitor and
mature luminal epithelial subsets isolated from the mouse
mammary gland and showed that they varied dramatically
amongst the two primary lineages and in response to
ovarian hormones [14]. To determine whether the ex-
pression of miRNAs in the mammary gland was subject
to epigenetic regulation, we utilized ChIP-seq data for
H3K4me3 and H3K27me3 (activation and repressivemarks, respectively) to investigate histone methylation of
the regulatory regions of miRNAs spanning a region 3 kb
upstream of their putative transcriptional start-site (TSS).
Scatter plots (Fig. 5a) of DE genes between the MaSC/
basal and luminal progenitor populations demonstrated
a positive correlation between miRNA expression and
H3K4me3 chromatin modifications, in which the up-
stream regions of the top 200 DE miRNAs were examined.
Conversely, H3K27me3 marks negatively correlated with
the top DE miRNAs between these subsets. Interestingly,
similar correlations could be seen upon interrogation of
luminal progenitor versus mature luminal cells (Fig. 5b),
specifically for H3K27 trimethylation. The heat map de-
picts the relative levels of H3K4me3 and H3K27me3 mod-
ifications across a 3 kb upstream region for the top 140
DE miRNAs (Fig. 5c) in the MaSC/basal versus luminal
progenitor subsets and the luminal progenitor versus ma-
ture luminal subsets. These represent miRNAs and genes
that are potentially involved in cell-fate decisions and lu-
minal differentiation, respectively. Representative track
file histograms for the MaSC/basal-specific miRs-34b/c,
miR-204 and miR-218, highlighting the distribution of
H3K27me3 and H3K4me3 peaks, are shown in Fig. 6a.
Overall, these data indicate that epigenetic modifications
play an important role in lineage restriction along the
mammary differentiation hierarchy.
Since Ezh2 is a core enzymatic subunit of the poly-
comb repressor complex that catalyzes K27 trimethyla-
tion on H3, we investigated the role of Ezh2-mediated
repression of miRNAs. MiRNAs were extracted from
MaSC/basal and luminal cells sorted from either control
or Ezh2-deficient mouse mammary glands, and quantita-
tive RT-PCR was then performed for the MaSC/basal-
specific miRNAs miR-34b, miR-204 and miR-218, as
their promoter regions were enriched for H3K27me3
marks in the luminal subsets (Fig. 6a). In Ezh2-deficient
glands, expression of these miRNAs was derepressed in
luminal cells, owing to loss of H3K27me3 (Fig. 6b). Con-
versely, we observed derepression of luminal-specific
miR-34a, miR-205 and miR-222 in the MaSC/basal sub-
set of Ezh2-deficient glands (data not shown). Together
these findings indicate that Ezh2 plays an important role
















































Fig. 3 The human MaSC/basal population is enriched for primate-specific miRNAs. Primate-specific miRNAs are expressed at higher levels in the
human MaSC/basal subset (MS) relative to luminal and stromal cells. a The primate-specific chromosome-19 miRNA cluster (C19MC) is located at
19q13.4, flanked by the DPRX and NLRP2 genes. C19MC is ~150 kb in length and codes for 50 known miRNAs. b Bar plots show normalized
average Ct values for 15 primate-specific miRNAs that are differentially expressed between the MaSC/basal (MS), mature luminal (ML), luminal
progenitor (LP) and stromal (str) cell subsets. Quantitative PCR data was normalized against the U6 small RNA (n = 3 independent biological samples;
error bars represent SEM). c The table shows known or putative mRNA targets of DE primate-specific miRNAs in human breast epithelium
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This study describes genome-wide miRNA expression
profiling of four distinct mouse and human subpopula-
tions that are highly enriched for MaSC/basal, luminal
progenitor, mature luminal and stromal cells. The four
subpopulations exhibited distinct miRNA signatures that
were conserved across species. Evaluation of potential
target genes revealed that the top differentially expressedmiRNAs likely target lineage-specific mRNAs. The pre-
dicted miRNA–mRNA relationships were found to be
highly conserved between mouse and human epithelial
subtypes. Around 58 % (25 miRNAs) of the top nega-
tively correlated miRNAs in the mouse mammary gland
(Additional file 8: Table S8) were conserved in human;
these miRNAs are likely to govern important mammary



























































































Fig. 4 Comparison of normal human breast epithelial miRNA signatures with miRNA profiles of different breast cancer subtypes. a The miRNA
signatures of human mammary epithelial subsets were used to identify relationships between normal human epithelial subsets and tumors of
different molecular subtypes. The miRNA signature scores of epithelial subsets were derived as MS vs LP+ML; LP vs MS+ML and ML vs MS+LP
(MS MaSC/basal, LP luminal progenitor, ML mature luminal). Panels show boxplots for the LP, MS and ML signature expression scores with respect
to the miRNA signatures of tumor subtypes derived from the TCGA database (breast cancer subtype: LumA luminal A, LumB luminal B, HER2
Human epidermal growth factor receptor 2 positive, Basal often triple negative tumors). b Expression of basal-restricted, primate-specific miRNAs
was examined in the different subtypes of breast cancer using the TCGA dataset. Boxplots are shown for miRNA-516a and miR-519a, where significant
enrichment was observed in the basal-like subtype. CPM, counts per million
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NAs include miR-30a/d (targets Runx2) [57], miR-148a
(targets Met/Snail) [58], miR-503 (targets Bcl-2 and
Igf1r, implicated in involution) [59], miR-203 (targets the
transcription factor p63) [60] and miR-34a (targets Dll1
and CD44, important for stem cell activity) [61, 62].
There is accumulating evidence that the Wnt and
Notch pathways, as well as the Polycomb repressor com-
plex of proteins, play prominent roles in regulating
MaSC function [14, 63–65]. In the context of miRNAs
that potentially control these pathways, we identified
several luminal-restricted miRNAs, including miR-10a,
miR-200a/b, miR-203, miR-148a. Conversely, miR-146a,
miR-221/222, and miR-205, which have been shown to
regulate genes expressed in the ductal and alveolar lu-
minal lineages (e.g., Brca1, Gata3, c-kit and Elf5), were
restricted to the MaSC/basal population.
Intriguingly, the primate-specific miRNA cluster (C19MC
miRNAs) on chromosome 19 at q13.4 was highly ex-
pressed in MaSC/basal cells. Moreover, miR-512 has beenimplicated in targeting the pro-survival gene MCL-1 that
is expressed at very low levels in this subset [66]. Our
Targetscan analysis further identified the luminal-specific
genes RANK, NOTCH3, ELF5, ESR1, HEY2 and KIT as po-
tential targets of these primate-specific miRNAs (Fig. 3c).
Notably, structural rearrangements of the chromosomal
19q13 region that occur in some thyroid adenomas and
adenomatous goiters are associated with aberrant expres-
sion of miRNAs in this cluster. In addition, miR-517c and
miR-591a are highly expressed in the basal-like subtype of
breast cancer [55], further implicating C19MC miRNAs in
carcinogenesis.
It has been presumed that the expression of miRNAs
and their host genes largely coincide. However, the ex-
pression of miRNAs located within introns or the coding
regions of specific genes may be independent of host
gene expression and its epigenetic modifications. For ex-
ample, expression of the BTG4 gene, which harbors the
MaSC/basal-specific miRNAs miR-34b and miR-34c,
and the TRP3 gene that encompasses miR-204, is not
Fig. 5 (See legend on next page.)
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Fig. 5 Correlation between miRNA expression and histone methylation patterns. The histone marks H3K4me3 and H3K27me3 correlate with
miRNA expression. Results are shown for the top 200 (scatter plot) or 140 (heatmap) differentially expressed miRNAs between the luminal
progenitor (LP) and MaSC/basal (MS) subsets and for the top 200 (scatter plot) or 140 (heatmap) differentially expressed (DE) miRNAs between the
mature luminal (ML) and LP subsets. a Scatter plots show that expression changes between the MS and LP subsets are directly correlated with
differential H3K4me3 marking (top panel, P = 0.017) and inversely correlated with H3K27me3 marking (bottom panel, P = 9.6 × 10-5). b Scatter
plots show that expression changes between the ML and LP subsets are uncorrelated with differential H3K4me3 marking (top panel, P = 0.4) but
inversely correlated with H3K27me3 marking (bottom panel, P = 0.108). c Heatmaps of expression and epigenetic changes. Vertical columns
represent log2-fold expression changes for expression, H3K4me3 binding and H3K27me3 binding, respectively. The left panel clusters the same
log-fold changes as for (a). The right panel clusters the same log-fold changes as for (b) (red = increased; blue = decreased). FC fold change
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MIB-1 gene, which is host to the MaSC/basal-specific
miRNAs miR-1 and miR-133a, is expressed at very low
levels in all three epithelial subsets (data not shown).
The epigenetic landscape of mammary epithelial cells
appears to play an important role in the progressive
commitment of MaSC/basal cells to differentiated cells.
Not only does the epigenome contribute to gene ex-
pression changes [14], but it tightly correlates with the
miRNA expression profiles of the different mouse mam-
mary epithelial subsets. Despite a paucity of information
on the TSS of miRNAs, a clear pattern has emerged for
histone methylation marks on DE miRNAs: the top DE
miRNAs repressed upon restriction of MaSC/basal cells
to luminal progenitor cells were enriched for H3K27me3
modifications, while those activated upon commitment
were characterized by the presence of H3K4me3 marks.
Similar epigenetic patterning held for the luminal pro-
genitor versus mature luminal populations. Overall, the
presence of H3K4me3 marks correlated tightly with
the expression of both miRNAs and mRNAs, while
H3K27me3 modifications negatively correlated with
their expression. Moreover, the histone methylase Ezh2
was directly implicated in coordinating H3K27 trimethyla-
tion of the regulatory regions of miRNAs whose expres-
sion was repressed. Collectively, these data suggest that
miRNA expression is regulated by epigenetic modifica-
tions and contributes to decisions on proliferation versus
differentiation in the mammary gland. It remains to be de-
termined whether steroid hormones also influence the
epigenome of regions flanking miRNA loci. In human
mammary epithelial cell lines, the expression of the miR-
200 family was recently found to be subject to epigenetic
regulation, whereby DNA methylation and histone modi-
fications were altered during the transition between
stem-like and nonstem states [67]. DNA methylation of
the miR-200c-141 cluster and polycomb group-mediated
histone methylation of the miR-200b-200a-429 cluster
resulted in repression at these loci [67]. Moreover,
H3K4me3 was found to be associated with active miRNAs
in colorectal cancer cell lines, whereas hypermethylation
of promoter CpG islands caused epigenetic silencing of
miR-124 and mir-34b/c [68–71].Comparison of miRNA signatures derived for distinct
mammary epithelial subsets from normal mammary tis-
sue with those of different breast cancer subtypes further
strengthened the molecular links that have been previ-
ously defined at the mRNA level. Specifically, the
miRNA signature of the luminal progenitor population
was most concordant with the basal-like cancer subtype,
the mature luminal cell-enriched population was closest
to the luminal B subtype, and the signature of the
MaSC/basal population was highest in the normal-like
subtype of cancer. These findings suggest that defined
cell types in normal breast tissue may be predisposed to
acquiring oncogenic events that result in specific types
of cancer. Notably, there was a strong correlation be-
tween the miRNA signatures of the luminal progenitor
cell and the basal-like subtype of cancer, also reflected in
their corresponding transcriptomes. This cell is the likely
‘cell of origin’ for basal-like cancers that arise in BRCA1
mutation carriers [2].
Several highly expressed miRNAs have been associated
with the development and progression of breast cancer,
in which their aberrant expression is presumed to
destabilize mRNAs encoding crucial tumor suppressors
and differentiation-promoting factors [72, 73]. Profiling
studies of primary breast tumors have revealed differen-
tial miRNA expression according to estrogen receptor
(ER)/progesterone receptor (PR) or human epidermal
growth factor receptor 2 (HER2) status and different
tumor stages [23, 55, 74, 75]. More specifically, the ex-
pression of some miRNAs has been linked to histo-
pathological features such as HER2/neu or ER/PR status
(miR-30), metastasis (miR-126 and miR-335) and the
EMT (miR-205 and miR-200 family) [43, 76–79]. The lu-
minal subtypes of breast cancer appear to have elevated
expression of miR-190b, while basal-like tumors have
higher levels of miR-18a/b, miR-9 and the miR-17-92
family and lower levels of miR-29 and miR-190b [55].
The higher levels of miR-18a/b, miR-9 and miR-17-92 in
the MaSC/basal population suggest that a subset of triple
negative cancers may harbor an expression signature that
more closely resembles that of the stem cell population.
Furthermore, the primate-specific, basal-restricted miR-
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Fig. 6 Ezh2 mediates repression of mammary epithelial miRNAs. MiR-34b, miR-204 and miR-218 are expressed highly in the MaSC/basal subset.
a Track files or read coverage graphs for H3K4me3 and H3K27me3 marks present in the 3 kb upstream region of miR-34b (top panel), miR-204
(middle panel) and miR-218 (bottom panel) in each epithelial subset. Y-axes show fragments per million on the scale 0–10. b Bar graphs represent
quantitative RT-PCR analysis for mammary epithelial cells isolated from control (Ezh2f/+) or Ezh2-deficient (MMTV-cre;Ezh2f/f) mammary glands.
Expression of the MaSC/basal-specific miRNAs miR-34b, miR-204 and miR-218 is upregulated in luminal cells of Ezh2-deficient samples compared
to littermate controls. Data was normalized against U6 small RNA. n = 3 independent biological samples; error bars show SEM. LP luminal progenitor,
ML mature luminal, MS MaSC/basal
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implicated in breast cancer include miR-100, shown to
target SMARCA5, SMARCD1, and BMPR2 genes, which
directly influence tumor cell proliferation [80], and miR-
30c, known to target TWF1 and IL-11 [81], both of which
are expressed in the MaSC/basal lineage. Ultimately, a
comprehensive analysis of miRNAs deregulated in breastcancer, together with an understanding of their transcrip-
tional and epigenetic control, may provide novel prognos-
tic or therapeutic tools for breast cancer.
Conclusions
These global miRNA profiles provide a valuable resource
for functional exploration of the molecular and epigenetic
Pal et al. Breast Cancer Research  (2015) 17:85 Page 14 of 16regulation of the mammary epithelial hierarchy. Here, our
analysis of distinct human and mouse epithelial subtypes
has highlighted potential miRNA networks responsible for
governing lineage commitment and differentiation in
mammary tissue. They further point to relationships be-
tween the signatures of normal cell types and intrinsic
breast cancer subtypes, supporting the notion that the cell
of origin may be an important determinant of tumor path-
ology. These relationships could be exploited to identify
improved biomarkers and small molecule inhibitors of
oncogenic pathways.Additional files
Additional file 1: Table S1. miRNAs that are differentially expressed
between mouse mammary stroma and total epithelium (MS + LP + ML).
Differential expression was assessed using a moderated t-test for each
miRNA. The Table shows log2 fold changes for stroma versus epithelium.
All miRNAs with FDR <0.05 are shown.
Additional file 2: Table S2. miRNAs that are differentially expressed
between human mammary stroma and total epithelium (MS + LP + ML).
Differential expression was assessed using a moderated t-test for each
miRNA. The Table shows log2 fold changes for stroma versus epithelium.
All miRNAs with FDR <0.05 are shown.
Additional file 3: Table S3. miRNAs that are differentially expressed
between the mouse mammary epithelial subsets: MaSC/basal (MS),
luminal progenitor (LP) and mature luminal (ML). Differential expression
was assessed using a moderated analysis of variance (ANOVA) F-test for
each miRNA between the three populations. The Table shows log2 fold
changes for LP versus MS and for ML versus LP. All miRNAs with
FDR <0.05 are shown.
Additional file 4: Table S4. miRNAs that are differentially expressed
between the human mammary epithelial subsets: MaSC/basal (MS),
luminal progenitor (LP) and mature luminal (ML). Differential expression
was assessed using a moderated analysis of variance (ANOVA) F-test for
each miRNA between the three populations. The Table shows log2 fold
changes for LP versus MS and for ML versus LP. All miRNAs with
FDR <0.05 are shown.
Additional file 5: Table S5. miRNAs that are differentially expressed in
the mouse MaSC/basal (MS) subset compared to the total luminal
compartment (LP + ML). Differential expression was assessed using a
moderated t-test for each miRNA. The Table shows log2 fold changes for
MS versus average luminal. All miRNAs with FDR <0.05 are shown.
Additional file 6: Table S6. miRNAs that are differentially expressed in
the human MaSC/basal (MS) subset compared to the total luminal
compartment (LP + ML). Differential expression was assessed using a
moderated t-test for each miRNA. The Table shows log2 fold changes for
MS versus average luminal. All miRNAs with FDR <0.05 are shown.
Additional file 7: Table S7. miRNAs that are consistently differentially
expressed between MaSC/basal (MS) and the total luminal compartment
in both mouse and human. Differential expression was assessed use a
moderated t-test for each miRNA using both mouse and human data.
The Table shows the consensus log2 fold changes for MS versus average
luminal across the two species.
Additional file 8: Table S8. ROAST tests for inverse correlation
between each DE miRNA and its putative mRNA targets in mouse (A)
and human (B). The Table shows the number of target genes, the one-
sided P-value and the FDR for each miRNA.
Additional file 9: Table S9. Gene ontology (GO) enrichment analysis of
mouse genes regulated by luminal cell-specific miRNAs (A) and MaSC/
basal-specific miRNAs (B) in the mouse mammary gland (Ontology
groups: MF molecular function, CC cellular function and BP biological
process).Additional file 10: Table S10. Gene ontology (GO) enrichment analysis
of human genes regulated by luminal cell-specific miRNAs (A) and MaSC/
basal-specific miRNAs (B) in the human mammary gland (Ontology
groups: MF molecular function, CC cellular function and BP biological
process).
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